SUPPLEMENTARY APPENDIX

Supplemental Table 1: MEDLINE Search Strategy – Ovid Interface

|  |
| --- |
| **MEDLINE search strategy – Ovid Interface** |
| 1 Hypertension/dt and (resistant or uncontrolled or refractory).tw. |
| 2 ((resistant or uncontrolled or refractory) adj3 (hypertens\* or blood pressure or bp)).tw. |
| 3 ATRH.tw. |
| 4 resistant hypertension.kw. |
| 5 or/1-4 |
| 6 Medication Adherence/ or Patient Compliance/ |
| 7 (adheren\* or nonadheren\* or complian\* or noncomplian\*).tw,kf. |
| 8 6 or 7 |
| 9 5 and 8 |
| 10 exp Cohort Studies/ |
| 11 (cohort or retrospective\* or prospective\*).tw,kf. |
| 12 Cross-Sectional Studies/ |
| 13 (cross-sectional or prevalence).tw,kw. |
| 14 randomized controlled trial.pt. |
| 15 controlled clinical trial.pt. |
| 16 randomi?ed.ab. |
| 17 placebo.ab. |
| 18 clinical trials as topic.sh. |
| 19 randomly.ab. |
| 20 trial.ti. |
| 21 or/10-20 |
| 22 9 and 21 |
| 23 (infant/ or child/) not adult/ |
| 24 22 not 23 |

Supplemental Figure 1: Regression of Mean Age on Logit Event Rate



Supplemental Figure 2: Regression of Proportion of Men on Logit Event Rate

Supplemental Figure 3: Regression of Publication date on Logit Event Rate



Supplemental Figure 4: Regression of Sample Size on Logit Event Rate



Supplemental Figure 5: Regression of Sample Size excluding one study on Logit Event Rate with Exclusion of One Large Study



|  |  |
| --- | --- |
|  | **Domains of the Newcastle-Ottawa Scale** |
| **Study** | **Representativeness of the exposed cohort** | **Selection of the non-exposed cohort** | **Ascertainment of exposure** | **Demonstration that outcome of interest was NOT present at start of study** | **Comparability of cohorts on the basis of design/analysis** | **Assessment of outcome** | **Was follow-up long enough for outcomes to occur?** | **Adequacy of cohort follow-up** | **Total Number of Stars** |
| **Avataneo**22 | A (\*) | N/A | N/A | A (\*) | N/A | A (\*) | A (\*) | A (\*) | 5 |
| **Azizi**28 | D | N/A | N/A | B | N/A | A (\*) | A (\*) | A (\*) | 3 |
| **Beaussier**29 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Brinker**11 | B (\*) | N/A | N/A | B | N/A | A (\*) | B | B (\*) | 3 |
| **Bunker**30 | B (\*) | N/A | N/A | A (\*) | N/A | A (\*) | A (\*) | A (\*) | 5 |
| **Burnier**31 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Ceral**32 | B (\*) | N/A | N/A | A (\*) | N/A | A (\*) | B | A (\*) | 4 |
| **Corrêa**23 | A (\*) | N/A | N/A | B | N/A | A (\*) | A (\*) | A (\*) | 4 |
| **Daugherty**33 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **de Jager**34 | B (\*) | N/A | N/A | B | N/A | A (\*) | A (\*) | B (\*) | 4 |
| **de Jesus**35 | A (\*) | N/A | N/A | B | N/A | C | A (\*) | A (\*) | 3 |
| **de Souza**36 | A (\*) | N/A | N/A | B | N/A | C | A (\*) | A (\*) | 3 |
| **Durand**24 | B (\*) | N/A | N/A | B | N/A | A (\*) | A (\*) | B (\*) | 4 |
| **Elmula**37 | B (\*) | N/A | N/A | B | N/A | A (\*) | A (\*) | A (\*) | 4 |
| **Ewen**38 | B (\*) | N/A | N/A | B | N/A | A (\*) | B | B (\*) | 3 |
| **Ewen**39 | A (\*) | N/A | N/A | A (\*) | N/A | A (\*) | B | A (\*) | 4 |
| **Florczak**21 | A (\*) | N/A | N/A | B | N/A | A (\*) | B | A (\*) | 3 |
| **Garg**40 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Grigoryan**41 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Hameed**42 | A (\*) | N/A | N/A | A (\*) | N/A | A (\*) | A (\*) | A (\*) | 5 |
| **Hayes**43 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Heimark**44 | A (\*) | N/A | N/A | B | N/A | A (\*) | A (\*) | A (\*) | 4 |
| **Irvin**45 | B (\*) | N/A | N/A | B | N/A | C | A (\*) | A (\*) | 3 |
| **Jung**46 | A (\*) | N/A | N/A | B | N/A | A (\*) | B | A (\*) | 3 |
| **Kociánová**47 | B (\*) | N/A | N/A | A (\*) | N/A | A (\*) | A (\*) | A (\*) | 5 |
| **Massierer**48 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Pandey**25 | B (\*) | N/A | N/A | A (\*) | N/A | A (\*) | B | C | 3 |
| **Porter**20 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | B (\*) | 4 |
| **Pucci**49 | A (\*) | N/A | N/A | B | N/A | A (\*) | B | A (\*) | 3 |
| **Rosa**50 | A (\*) | N/A | N/A | B | N/A | A (\*) | A (\*) | A (\*) | 4 |
| **Ruzicka**26 | B (\*) | N/A | N/A | A (\*) | N/A | A (\*) | A (\*) | B (\*) | 5 |
| **Schmieder**51 | A (\*) | N/A | N/A | B | N/A | A (\*) | B | A (\*) | 3 |
| **Sim**19 | B (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| **Štrauch**27 | A (\*) | N/A | N/A | A (\*) | N/A | A (\*) | A (\*) | A (\*) | 5 |
| **Velasco**52 | B (\*) | N/A | N/A | A (\*) | N/A | A (\*) | B | A (\*) | 4 |
| **Yakovlevitch**53 | A (\*) | N/A | N/A | B | N/A | B (\*) | A (\*) | A (\*) | 4 |
| *Detail of abbreviations*: **N/A** – Non-Applicable |

Supplemental Table 2: Quality Assessment

Supplemental Figure 6: Funnel Plot of Included Studies

